Lin, Jessica J.
Langenbucher, Adam
Gupta, Pranav
Yoda, Satoshi http://orcid.org/0000-0003-4201-1392
Fetter, Isobel J.
Rooney, Marguerite http://orcid.org/0000-0002-4996-0737
Do, Andrew http://orcid.org/0000-0002-5782-5818
Kem, Marina
Chang, Kylie Prutisto http://orcid.org/0000-0003-2845-2458
Oh, Audris Y.
Chin, Emily
Juric, Dejan
Corcoran, Ryan B. http://orcid.org/0000-0001-8173-5778
Dagogo-Jack, Ibiayi
Gainor, Justin F.
Stone, James R.
Lennerz, Jochen K. http://orcid.org/0000-0003-2434-4978
Lawrence, Michael S.
Hata, Aaron N.
Mino-Kenudson, Mari
Shaw, Alice T.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA164273, R01CA225655)
Be a Piece of the Solution (MGH), Targeting a Cure for Lung Cancer Research Fund
Susan Eid Tumor Heterogeneity Initiative
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 21 February 2020
Accepted: 5 June 2020
First Online: 3 August 2020
Competing interests
: J.J.L. has served as a compensated consultant or received honorarium from Chugai Pharma, Boehringer-Ingelheim, Pfizer, C4 Therapeutics, Nuvalent, Genentech, and Turning Point Therapeutics; received institutional research funds from Hengrui Therapeutics, Turning Point Therapeutics, Neon Therapeutics, and Novartis; received CME funding from OncLive; and received travel support from Pfizer. D.J. has received scientific advisory board fee from Eisai, EMD Serono, Genentech, Ipsen, Novartis, Guardant, Petra Pharma, Vibliome Therapeutics, and Relay Therapeutics, and institutional research funds from Novartis, Genentech, EMD Serono, Eisai, Takeda, Placon Therapeutics, Takeda, and Amgen. R.B.C. has served as a consultant/advisory board member for Amgen, Array Biopharma, Astex Pharmaceuticals, Avidity Biosciences, BMS, C4 Therapeutics, Chugai, Elicio, Fog Pharma, Fount Therapeutics/Kinnate Biopharma, Genentech, Guardant Health, Ipsen, LOXO, Merrimack, Natera, N-of-one, Novartis, nRichDx, Revolution Medicines, Roche, Roivant, Shionogi, Shire, Spectrum Pharmaceuticals, Symphogen, Taiho, Warp Drive Bio, Zikani Therapeutics; holds equity in Avidity Biosciences, C4 Therapeutics, Fount Therapeutics, nRichDx, and Revolution Medicines; and has received research funding from Asana, AstraZeneca, Lilly, and Sanofi. I.D.-J. has served as a compensated consultant or received honorarium from Boehringer-Ingelheim and Foundation Medicine, and has received research support from Guardant Health, Array, Pfizer, and Genentech. J.F.G. has served as a compensated consultant or received honoraria from Bristol-Myers Squibb, Genentech, Ariad/Takeda, Loxo, Blueprint, Oncorus, Regeneron, Pfizer, Incyte, Novartis, Merck, Agios, Amgen, Array, and Clovis Oncology; research support from Novartis, Genentech/Roche, and Ariad/Takeda; institutional research support from Bristol-Myers Squibb, Tesaro, Moderna, Blueprint, Jounce, Array Biopharma, Merck, Adaptimmune, Novartis, and Alexo; and has an immediate family member who is an employee of Ironwood Pharmaceuticals. A.N.H. has received research support from Pfizer, Novartis, Amgen, Roche/Genentech, Eli Lilly, and Relay Therapeutics. M.M.-K. has served as a compensated consultant for H3 Biomedicine and AstraZeneca; institutional research support from Novartis. A.T.S. has served as a compensated consultant or received honoraria from Pfizer, Novartis, Genentech/Roche, Ariad/Takeda, Ignyta, LOXO, Bayer, Chugai, Blueprint Medicines, KSQ Therapeutics, Daiichi Sankyo, EMD Serono, Taiho Pharmaceutical, TP Therapeutics, Servier, Syros, Foundation Medicine, Guardant, Natera, Achilles, and Archer; has received institutional research funding from Pfizer, Novartis, Roche/Genentech, Ariad, Ignyta, and TP Therapeutics; has received travel support from Pfizer and Genentech; and is currently an employee of Novartis. The remaining authors have no financial interests to declare.